Free Trial

Astrana Health (NASDAQ:ASTH) Shares Down 4.9% - Here's Why

Astrana Health logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Astrana Health shares fell 4.9% to $23.50 on Tuesday, with just 66,338 shares changing hands — an 88% decline from average session volume, after a prior close of $24.72.
  • Analysts are mixed: five Buy, one Hold and two Sell ratings result in an average rating of "Hold" with a $35.33 target, while several firms have recently trimmed price targets (e.g., BTIG $45→$40, TD Cowen $40→$35).
  • The company reported a quarterly beat (EPS $0.54 vs. $0.15 estimate; revenue $950.5M vs. $930.5M), with revenue up 42.9% year-over-year and a market cap of about $1.33 billion (PE ~51.4).
  • Five stocks to consider instead of Astrana Health.

Astrana Health, Inc. (NASDAQ:ASTH - Get Free Report) fell 4.9% during trading on Tuesday . The company traded as low as $23.19 and last traded at $23.50. 66,338 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 569,915 shares. The stock had previously closed at $24.72.

Analyst Upgrades and Downgrades

ASTH has been the topic of several research reports. BTIG Research cut their price target on shares of Astrana Health from $45.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. Jefferies Financial Group reaffirmed a "buy" rating on shares of Astrana Health in a report on Tuesday, November 25th. Zacks Research lowered shares of Astrana Health from a "hold" rating to a "strong sell" rating in a research note on Tuesday, February 10th. Needham & Company LLC assumed coverage on shares of Astrana Health in a report on Friday, December 12th. They set a "buy" rating and a $28.00 target price for the company. Finally, TD Cowen lowered their price target on shares of Astrana Health from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Monday, November 10th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $35.33.

View Our Latest Stock Analysis on Astrana Health

Astrana Health Trading Down 4.3%

The firm has a market cap of $1.33 billion, a PE ratio of 51.38 and a beta of 0.91. The company has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $26.11. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.25.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Monday, March 2nd. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.39. Astrana Health had a net margin of 0.71% and a return on equity of 5.59%. The firm had revenue of $950.53 million during the quarter, compared to analyst estimates of $930.46 million. During the same period in the previous year, the firm earned ($0.15) EPS. The business's quarterly revenue was up 42.9% on a year-over-year basis. As a group, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Several hedge funds have recently modified their holdings of the company. Signaturefd LLC increased its stake in shares of Astrana Health by 57.9% in the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company's stock valued at $26,000 after purchasing an additional 388 shares in the last quarter. Amalgamated Bank boosted its position in Astrana Health by 3.4% during the third quarter. Amalgamated Bank now owns 12,325 shares of the company's stock worth $349,000 after purchasing an additional 409 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Astrana Health by 1.5% during the third quarter. Thrivent Financial for Lutherans now owns 30,977 shares of the company's stock worth $878,000 after purchasing an additional 455 shares in the last quarter. Principal Financial Group Inc. grew its holdings in Astrana Health by 0.3% in the third quarter. Principal Financial Group Inc. now owns 222,985 shares of the company's stock valued at $6,322,000 after purchasing an additional 611 shares during the period. Finally, Savant Capital LLC increased its position in shares of Astrana Health by 2.2% in the third quarter. Savant Capital LLC now owns 30,713 shares of the company's stock valued at $871,000 after buying an additional 649 shares in the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Astrana Health Right Now?

Before you consider Astrana Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.

While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines